Bank of Stockton Acquires 352 Shares of Sanofi (NASDAQ:SNY)

Bank of Stockton raised its holdings in shares of Sanofi (NASDAQ:SNYFree Report) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,251 shares of the company’s stock after acquiring an additional 352 shares during the period. Bank of Stockton’s holdings in Sanofi were worth $301,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Synergy Asset Management LLC bought a new position in shares of Sanofi in the fourth quarter worth approximately $25,000. Concord Wealth Partners grew its holdings in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the last quarter. McClarren Financial Advisors Inc. grew its holdings in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Sunbelt Securities Inc. grew its holdings in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the last quarter. Finally, Fortitude Family Office LLC grew its holdings in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

NASDAQ:SNY opened at $54.13 on Friday. The stock has a market cap of $137.37 billion, a P/E ratio of 21.74, a price-to-earnings-growth ratio of 1.00 and a beta of 0.57. The firm’s fifty day simple moving average is $50.79 and its 200 day simple moving average is $52.50. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNYGet Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts predict that Sanofi will post 4.36 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Read Our Latest Analysis on Sanofi

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.